PAD
MCID: PRP027
MIFTS: 69

Peripheral Vascular Disease (PAD) malady

Categories: Cardiovascular diseases

Aliases & Classifications for Peripheral Vascular Disease

Aliases & Descriptions for Peripheral Vascular Disease:

Name: Peripheral Vascular Disease 39 38 12 3 14
Arterial Occlusive Disease 39 38 12 14
Peripheral Arterial Disease 39 41 3
Arterial Occlusive Diseases 52 42 69
Peripheral Vascular Diseases 52 69
Helicobacter Infections 42 69
Pad 39 3
Peripheral Occlusive Disease 39
Peripheral Arterial Diseases 69

Classifications:



External Ids:

Disease Ontology 12 DOID:341
ICD9CM 35 443.81
SNOMED-CT 64 195624006 2929001
ICD10 33 I73.8

Summaries for Peripheral Vascular Disease

MedlinePlus : 41 peripheral arterial disease (pad) happens when there is a narrowing of the blood vessels outside of your heart. the cause of pad is atherosclerosis. this happens when plaque builds up on the walls of the arteries that supply blood to the arms and legs. plaque is a substance made up of fat and cholesterol. it causes the arteries to narrow or become blocked. this can reduce or stop blood flow, usually to the legs. if severe enough, blocked blood flow can cause tissue death and can sometimes lead to amputation of the foot or leg. the main risk factor for pad is smoking. other risk factors include older age and diseases like diabetes, high blood cholesterol, high blood pressure, heart disease, and stroke. many people who have pad don't have any symptoms. if you have symptoms, they may include pain, numbness, achiness, or heaviness in the leg muscles. this happens when walking or climbing stairs. weak or absent pulses in the legs or feet sores or wounds on the toes, feet, or legs that heal slowly, poorly, or not at all a pale or bluish color to the skin a lower temperature in one leg than the other leg poor nail growth on the toes and decreased hair growth on the legs erectile dysfunction, especially among men who have diabetes pad can increase your risk of heart attack, stroke, and transient ischemic attack. doctors diagnose pad with a physical exam and heart and imaging tests. treatments include lifestyle changes, medicines, and sometimes surgery. lifestyle changes include dietary changes, exercise, and efforts to lower high cholesterol levels and high blood pressure. nih: national heart, lung, and blood institute

MalaCards based summary : Peripheral Vascular Disease, also known as arterial occlusive disease, is related to artery disease and limb ischemia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Peripheral Vascular Disease is VWF (Von Willebrand Factor), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Cell surface interactions at the vascular wall. The drugs Cilostazol and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include Bone, bone and heart, and related phenotypes are Decreased free cholesterol and cardiovascular system

Disease Ontology : 12 A vascular disease that is characterized by obstruction of larger arteries not within the coronary, aortic arch vasculature, or brain.

CDC : 3 Peripheral Arterial Disease (PAD) in the Legs or lower extremities is the narrowing or blockage of the vessels that carry blood from the heart to the legs. It is primarily caused by the buildup of fatty plaque in the arteries, which is called atherosclerosis. PAD can occur in any blood vessel, but it is more common in the legs than the arms.

Related Diseases for Peripheral Vascular Disease

Diseases related to Peripheral Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 297)
id Related Disease Score Top Affiliating Genes
1 artery disease 30.1 CRP F2 F3
2 limb ischemia 29.6 ACE CRP IL6 SELP
3 lupus erythematosus 28.6 ACE CRP F3 IL6 PLAT SELP
4 myocardial infarction 26.7 ACE ALB APOA1 APOB CRP F2
5 peripheral artery disease 12.4
6 peripheral arterial occlusive disease 1 12.2
7 arterial occlusive disease, progressive, with hypertension, heart defects, bone fragility, and brachysyndactyly 12.1
8 buerger disease 11.4
9 vascular disease 10.8
10 priapism 10.7
11 intermittent claudication 10.5
12 urogenital adysplasia 10.3 THBD VWF
13 spondyloarthropathy 2 10.3 ACE ALB VEGFA
14 enamel hypoplasia cataract hydrocephaly 10.2 PLAT THBD VWF
15 deafness, autosomal recessive 79 10.2 ACE CRP VWF
16 zellweger syndrome 10.2 ALB VEGFA VWF
17 ependymoblastoma 10.2 ALB SELP VCAM1
18 schizotypal personality disorder 10.2 ACE ALB CRP
19 dermatomycosis 10.2 ALB CRP SELE
20 phlegmonous dacryocystitis 10.2 SELE VCAM1 VEGFA
21 ceroid lipofuscinosis, neuronal, kufs type, adult onset 10.2 ACE CRP VWF
22 vernal conjunctivitis 10.2 ACE ALB VEGFA
23 neonatal diabetes mellitus 10.2 SELE THBD VWF
24 melorheostosis 10.2 ACE PLAT SERPINC1
25 bile duct mucoepidermoid carcinoma 10.2 ALB CRP VWF
26 testicular lymphoma 10.2 ACE CRP SELE SELP
27 nondystrophic myotonia 10.2 ALB F2
28 albinism, oculocutaneous, type v 10.2 APOA1 APOB LPA
29 immunodeficiency 32a, mycobacteriosis, autosomal dominant 10.2 PLAT THBD
30 acute infection of pinna 10.2 CRP F2
31 cataract 10.1 ALB CRP SERPINC1
32 bird fancier's lung 10.1 APOA1 APOB LPA
33 skin squamous cell carcinoma 10.1 APOA1 APOB LPA
34 chondrocalcinosis with early-onset osteoarthritis 10.1 APOA1 APOB LPA
35 familial progressive hyperpigmentation 10.1 ACE F2
36 anaplastic ganglioglioma 10.1 APOA1 CRP LPA
37 hereditary endotheliopathy, retinopathy, nephropathy, and stroke 10.1 F3 SELP SERPINC1
38 myopia 10.1 ACE ALB F2
39 hypertrichosis 10.1 F3 SERPINC1 VWF
40 villous adenoma 10.1 ACE CRP F2
41 inflammatory bowel disease 11 10.1 PLAT SERPINE1
42 subclavian artery aneurysm 10.1 F3 SELP SERPINE1
43 hypertriglyceridemia 10.1 APOA1 APOB LPA
44 alpha-2-macroglobulin deficiency 10.1 F2 F3 VWF
45 carbohydrate metabolic disorder 10.1 ACE SERPINC1
46 familial periodic paralysis 10.1 ACE CRP F2
47 arcus senilis 10.1 CRP F3 SERPINE1
48 pulpitis 10.1 F2 THBD VWF
49 fletcher factor deficiency 10.1 F2 F3 VWF
50 brazilian hemorrhagic fever 10.1 PLAT SERPINC1 SERPINE1

Comorbidity relations with Peripheral Vascular Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 98)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Anxiety Disorder Aortic Aneurysm
Aortic Atherosclerosis Autonomic Nervous System Disease
Basilar Artery Insufficiency Benign Essential Hypertension
Benign Renovascular Hypertension Bleeding Disorder, Platelet-Type, 11
Bronchitis Bronchopneumonia
Buerger Disease Cardiac Arrest
Cardiogenic Shock Cerebral Atherosclerosis
Cerebrovascular Disease Chronic Kidney Failure
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Chronic Ulcer of Skin Decubitus Ulcer
Deficiency Anemia Dermatomycosis
Diabetic Peripheral Angiopathy Diabetic Polyneuropathy
Dressler's Syndrome Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gas Gangrene
Generalized Atherosclerosis Gout
Heart Conduction Disease Heart Disease
Hyperlipidemia, Familial Combined Hyperlipoproteinemia Type Iv
Hypertension, Essential Hypertensive Encephalopathy
Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Intracranial Embolism

Graphical network of the top 20 diseases related to Peripheral Vascular Disease:



Diseases related to Peripheral Vascular Disease

Symptoms & Phenotypes for Peripheral Vascular Disease

UMLS symptoms related to Peripheral Vascular Disease:


angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Peripheral Vascular Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.92 APOA1 APOB LPA SELP

MGI Mouse Phenotypes related to Peripheral Vascular Disease:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 SERPINE1 THBD VCAM1 VEGFA VWF ACE
2 homeostasis/metabolism MP:0005376 10.42 ACE ALB APOA1 APOB CRP F2
3 immune system MP:0005387 10.35 PLAT SELE SELP SERPINC1 SERPINE1 THBD
4 cellular MP:0005384 10.33 ALB APOA1 APOB F3 IL6 PLAT
5 hematopoietic system MP:0005397 10.32 SELE SELP SERPINC1 SERPINE1 THBD VCAM1
6 growth/size/body region MP:0005378 10.3 ACE APOB F2 F3 IL6 PLAT
7 mortality/aging MP:0010768 10.28 ACE ALB APOB F2 F3 IL6
8 liver/biliary system MP:0005370 10.17 ACE ALB APOA1 APOB IL6 SELE
9 integument MP:0010771 10.11 SELP SERPINE1 THBD VEGFA APOA1 F2
10 digestive/alimentary MP:0005381 10.08 ALB F2 IL6 PLAT THBD VEGFA
11 nervous system MP:0003631 10.02 THBD VEGFA VWF APOB F2 F3
12 renal/urinary system MP:0005367 9.86 ACE ALB IL6 SELP SERPINC1 SERPINE1
13 neoplasm MP:0002006 9.85 ACE ALB F3 IL6 SERPINE1 VEGFA
14 reproductive system MP:0005389 9.81 ACE APOB F2 IL6 PLAT SERPINC1
15 respiratory system MP:0005388 9.61 SERPINE1 THBD VEGFA F2 F3 IL6
16 vision/eye MP:0005391 9.23 PLAT SELE SELP SERPINC1 VEGFA APOB

Drugs & Therapeutics for Peripheral Vascular Disease

Drugs for Peripheral Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1474)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 73963-72-1 2754
2
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
3
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 2180-92-9, 38396-39-3 2474
4
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4205-90-7 2803
5
Levobupivacaine Approved Phase 4,Phase 2,Phase 3 27262-47-1 92253
6
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 57-27-2 5288826
7
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
8
Pravastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 81093-37-0 54687
9
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2 75847-73-3 5362032 40466924
10
Enalaprilat Approved Phase 4,Phase 3,Phase 2 76420-72-9 6917719
11
Rimonabant Approved, Investigational Phase 4,Phase 3 168273-06-1, 158681-13-1 104850
12
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 79902-63-9 54454
13
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
14
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757 53477783
15
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2 57-83-0 5994
16
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 33069-62-4 36314
17
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
19
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
20
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55142-85-3 5472
21
Fluvastatin Approved Phase 4,Phase 3 93957-54-1 1548972
22
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10102-43-9 145068
23
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1 274693-27-5 9871419
24
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
25
Tirofiban Approved Phase 4,Phase 3,Phase 1 144494-65-5 60947
26
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55-56-1 9552079 2713
27
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 88150-42-9 2162
28
Ranolazine Approved, Investigational Phase 4,Phase 2,Phase 3 142387-99-3, 95635-55-5 56959
29
Ezetimibe Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 163222-33-1 150311
30
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2 128270-60-0 16129704
31
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 37350-58-6, 51384-51-1 4171
32
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-61-7 60961
33
Dipyridamole Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-32-2 3108
34
Regadenoson Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 313348-27-5 219024
35
Esmolol Approved Phase 4,Phase 3 103598-03-4, 81147-92-4 59768
36
Nicardipine Approved Phase 4,Phase 3 55985-32-5 4474
37
Coal tar Approved Phase 4,Phase 1,Phase 2 8007-45-2
38
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 73590-58-6 4594
39
Pantoprazole Approved Phase 4,Phase 2,Phase 3 102625-70-7 4679
40
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
41
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
42
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 111025-46-8 4829
43
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
44
Nicorandil Approved Phase 4 65141-46-0 47528
45
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Early Phase 1 58-18-4 6010
46
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 58-22-0 6013
47
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
48
Olmesartan Approved, Investigational Phase 4,Phase 3 144689-24-7, 144689-63-4 158781 130881
49
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1
50
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091

Interventional clinical trials:

(show top 50) (show all 9243)
id Name Status NCT ID Phase
1 A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease Unknown status NCT01711333 Phase 4
2 Comparison of Stent and Prothesis Bypass in Superficial Femoral Artery Unknown status NCT01147419 Phase 4
3 Interest of a Bi-truncal Nerve Block (Femoral + Sciatic) Extended, Systematically Associated With General Anesthesia, in the Femoropopliteal Bypass: Study of Post-operative Analgesia and Peripheral Circulation Downstream Unknown status NCT01785693 Phase 4
4 ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion Unknown status NCT00407940 Phase 4
5 Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia Unknown status NCT00403780 Phase 4
6 The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4
7 Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4
8 Homocysteine Lowering and Atherosclerosis Reduction Trial (HART) Unknown status NCT00217178 Phase 4
9 Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4
10 Sufficient Treatment of Peripheral Intervention by Cilostazol Unknown status NCT00912756 Phase 4
11 Does Rosuvastatin Delay Progression of Atherosclerosis in HIV Unknown status NCT01813357 Phase 4
12 Kronos Early Estrogen Prevention Study (KEEPS) Unknown status NCT00154180 Phase 4
13 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROL Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease Unknown status NCT01653600 Phase 4
14 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4
15 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4
16 Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease Unknown status NCT00986752 Phase 4
17 Paclitaxel Eluting Balloon and Conventional Balloon for In-Stent Restenosis of the Superficial Femoral Artery Unknown status NCT01083394 Phase 4
18 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4
19 Fractional Flow Reserve Versus Angiography Randomization for Graft Optimization Trial Unknown status NCT02477371 Phase 4
20 The ABC Trial Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery? A Single Centre Pilot Study Unknown status NCT01623193 Phase 4
21 Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions Unknown status NCT00640744 Phase 4
22 Fluvastatin AmelIorates aTHerosclerosis Study Unknown status NCT01681199 Phase 4
23 Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study Unknown status NCT01064323 Phase 4
24 The Effect of Vitamin A on Atherosclerosis Unknown status NCT01414972 Phase 4
25 The Study of the Effects of Vitamin A on Immune System in Patients With Atherosclerosis Unknown status NCT00963222 Phase 4
26 Relation Among Shear Stress Distribution, Stent Design, and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
27 Intracoronary Stenting and Angiographic Results: ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography Unknown status NCT01594736 Phase 4
28 Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing Unknown status NCT01456364 Phase 4
29 Test of Long-Term Safety and Efficacy of Sirolimus-Permanent-Polymer Eluting Stent (Cypher)- and Sirolimus-Polymer-free Eluting Stents (PPS/PFS) Assessed by Optical Coherence Tomography Unknown status NCT01260558 Phase 4
30 Test Safety and Efficacy of Zotarolimus- and Everolimus-Eluting Stents (ZES/EES) Assessed by Optical Coherence Tomography Unknown status NCT01230723 Phase 4
31 Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents Unknown status NCT01068106 Phase 4
32 The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients Unknown status NCT00470808 Phase 4
33 The Effect of Dates on Plasma Lipids, Oxidative Stress and the Atherogenicity of Serum in Healthy Adults Unknown status NCT00750789 Phase 4
34 Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4
35 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease Unknown status NCT01508663 Phase 4
36 Residual Platelet Activity In Advanced Peripheral Artery Disease Unknown status NCT01627431 Phase 4
37 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4
38 Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
39 The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4
40 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4
41 Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients Unknown status NCT02001883 Phase 4
42 Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears Unknown status NCT02004730 Phase 4
43 Xience/Promus for Long Coronary Lesion Registry Unknown status NCT01147237 Phase 4
44 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
45 Efficacy and Safety of Paclitaxel-eluting Balloon for Treatment of Lesions in Native Small Coronary Arteries Unknown status NCT01903902 Phase 4
46 Periodontal Therapy in Coronary Artery Patients Unknown status NCT01609725 Phase 4
47 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4
48 Safety and Effectiveness of the Coronary Momo Stent Unknown status NCT01535625 Phase 4
49 Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns Unknown status NCT01024179 Phase 4
50 Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity Unknown status NCT01490255 Phase 4

Search NIH Clinical Center for Peripheral Vascular Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Peripheral Vascular Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Peripheral Vascular Disease:
ACY001, bone marrow-derived hematopoietic stem cells for coronary artery occlusions
ALD-301, bone marrow-derived cells for critical limb ischemia
Alecmestencel-T, mesenchymal stem cells for ischemic diseases
ALO212, umbilical cord blood-derived stem cell concentrate for vascular diseases
Autologus endothelial progenitor cells for the treatment of critical limb ischemia
Autologus hematopoeitic stem cells for the treatment of critical limb ischemia
Bone marrow-derived CD133+ or nucleated cells for peripheral artery disease
Bone marrow-derived mononuclear cells for peripheral vascular disease
Bone marrow-derived mononuclear stem cells for treatment of critical limb ischemia
Endothelial progenitor cells for peripheral artery disease
Enriched bone marrow-derived progenitor cells for ischemic diseases
MultiGeneAngio, genetically modified endothelial and smooth muscle cells for vascular disease
MultiStem
Peripheral blood-derived hematopoietic stem cells for leg gangrene
TGI PVG, adipose-derived stem cell-coated vascular graft for peripheral vascular disease
VASCUGEL
Embryonic/Adult Cultured Cells Related to Peripheral Vascular Disease:
Bone marrow-derived CD133+ stem cells
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905 19324906
Bone marrow-derived mesenchymal stem cells (family)
Cord blood-derived hematopoietic stem cell PMIDs: 19558779
Peripheral blood-derived endothelial cells PMIDs: 19448678 18388019
Peripheral blood-derived hematopoietic stem cells PMIDs: 18388019
Bone marrow-derived mononuclear cells (family)
Bone marrow-derived mononuclear cells
Bone marrow-derived mononuclear cells
Peripheral blood-derived endothelial progenitor cells PMIDs: 10725398
Bone marrow-derived progenitor cells
MultiGeneAngio, transduced vein-derived endothelial cells
MultiGeneAngio, transduced vein-derived smooth muscle cells
Genetically modified vein-derived smooth muscle
Genetically modified vein-derived endothelial cells
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 21175285 23307829
Peripheral blood-derived hematopoietic stem cells
Adipose-derived stromal cells PMIDs: 8207032 23350681
Aortic endothelial cells cultured in matrix PMIDs: 7667257
Aortic endothelial cells cultured in matrix (VASCUGEL PMIDs: 7667257

Cochrane evidence based reviews: arterial occlusive diseases

Genetic Tests for Peripheral Vascular Disease

Anatomical Context for Peripheral Vascular Disease

MalaCards organs/tissues related to Peripheral Vascular Disease:

39
Bone, Heart, Endothelial, Skin, Testes, Lung, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Peripheral Vascular Disease:
id Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Peripheral Vascular Disease

Articles related to Peripheral Vascular Disease:

(show top 50) (show all 573)
id Title Authors Year
1
Non-reconstructable peripheral vascular disease of the lower extremity in ten patients treated with adipose-derived stromal vascular fraction cells. ( 27984756 )
2017
2
Polyarteritis nodosa presenting as peripheral vascular disease and acute limb ischemia. ( 27853042 )
2017
3
Peripheral vascular disease in diabetic foot- A new trend. ( 27727607 )
2016
4
An Experimental Model of Peripheral Vascular Disease Involving the Intravenous Injection of Oral Bacteria. ( 28018496 )
2016
5
Comparison of colour duplex ultrasound & ankle brachial index in peripheral vascular disease in type 2 diabetes. ( 27727957 )
2016
6
Anesthesia for Patients with Peripheral Vascular Disease and Cardiac Dysfunction. ( 27816134 )
2016
7
Increased peripheral vascular disease risk progressively constrains perfusion adaptability in the skeletal muscle microcirculation. ( 26702145 )
2016
8
Mortality After Nontraumatic Major Amputation Among Patients WithA Diabetes and Peripheral Vascular Disease: A Systematic Review. ( 26898398 )
2016
9
Mitochondrial Respiration after One Session of Calf Raise Exercise in Patients with Peripheral Vascular Disease and Healthy Older Adults. ( 27760222 )
2016
10
Hemorheological parameters better classify metabolic syndrome than novel cardiovascular risk factors and peripheral vascular disease marker. ( 26890105 )
2016
11
Prevalence of asymptomatic peripheral vascular disease in patients with type-2 diabetes mellitus by colour doppler study. ( 27728049 )
2016
12
Trimetazidine hydrochloride as a new treatment for patients with peripheral vascular disease--an exploratory trial. ( 26813473 )
2016
13
Identifying beliefs about smoking in patients with peripheral vascular disease. ( 27863591 )
2016
14
SPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular disease. ( 27517840 )
2016
15
Transcatheter Aortic Valve Implantation in Patients With Arterial Peripheral Vascular Disease. ( 27884643 )
2016
16
Utility of Indocyanine Green Angiography in Arterial Selection during Free Flap Harvest in Patients with Severe Peripheral Vascular Disease. ( 27826489 )
2016
17
Treatment of a High-Risk Diabetic Patient with Peripheral Vascular Disease and Osteomyelitis. ( 27423990 )
2016
18
Neutrophil lymphocyte ratio in peripheral vascular disease: a review. ( 26967241 )
2016
19
The Discovery of Novel Genomic, Transcriptomic, and Proteomic Biomarkers in Cardiovascular and Peripheral Vascular Disease: The State of the Art. ( 27298828 )
2016
20
Peripheral Vascular Disease and Death in Southern European Kidney Transplant Candidates: A Competing Risk Modeling Approach. ( 27379552 )
2016
21
Evaluation of a novel 2D perfusion angiography technique independent of pump injections for assessment of interventional treatment of peripheral vascular disease. ( 27785678 )
2016
22
Association between Bacterial Infection and Peripheral Vascular Disease: A Review. ( 26900306 )
2016
23
Ventricular Tachycardia: Inferior Vena Cava Filter in a Case of Peripheral Vascular Disease. ( 26794288 )
2016
24
Novel Applications of Radionuclide Imaging in Peripheral Vascular Disease. ( 26590787 )
2016
25
Microsecond-pulsed dielectric barrier discharge plasma stimulation of tissue macrophages for treatment of peripheral vascular disease. ( 26543345 )
2015
26
Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: focus on skin and soft-tissue infections. ( 26198368 )
2015
27
A balloon-expandable sheath facilitates transfemoral TAVR in patients with peripheral vascular disease and tortuosity. ( 25784499 )
2015
28
EARLY EXPERIENCE OF ENDOVASCULAR TREATMENT OF PERIPHERAL VASCULAR DISEASE. ( 26182747 )
2015
29
Assessment of risk of peripheral vascular disease and vascular care capacity in a low- and middle-income country. ( 26560502 )
2015
30
Complex nonlinear autonomic nervous system modulation link cardiac autonomic neuropathy and peripheral vascular disease. ( 25870563 )
2015
31
Radiotracer Imaging of Peripheral Vascular Disease. ( 26338845 )
2015
32
How should I treat a complex critical left main bifurcation lesion in a patient with poor left ventricular function, an occluded dominant right coronary artery and severe peripheral vascular disease? ( 25692609 )
2015
33
Peripheral vascular disease: shaping a new panvascular interventional approach. ( 26603982 )
2015
34
Sustained release nitrite therapy results in myocardial protection in a porcine model of metabolic syndrome with peripheral vascular disease. ( 25957218 )
2015
35
Cost-effectiveness of medical, endovascular and surgical management of peripheral vascular disease. ( 26238266 )
2015
36
Thoracic sympathectomy for peripheral vascular disease can lead to severe bronchospasm and excessive bronchial secretions. ( 25624604 )
2015
37
Comparison of vancomycin and linezolid in patients with peripheral vascular disease and/or diabetes in an observational European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus. ( 26198370 )
2015
38
Nanoscale Strategies: Treatment for Peripheral Vascular Disease and Critical Limb Ischemia. ( 25844518 )
2015
39
A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. ( 25533300 )
2015
40
Advances in axial imaging of peripheral vascular disease. ( 26285590 )
2015
41
Microvascular perfusion heterogeneity contributes to peripheral vascular disease in metabolic syndrome. ( 25384789 )
2014
42
Decade in review-peripheral vascular disease: 10 Years of breakthroughs in peripheral vascular disease. ( 25267425 )
2014
43
Association of bilateral brachial-ankle pulse wave velocity difference with peripheral vascular disease and left ventricular mass index. ( 24551090 )
2014
44
Myocardial ischemia in a patient with peripheral vascular disease, an arteriovenous fistula, and patent coronary artery bypass grafts. ( 25027049 )
2014
45
Interarm difference in blood pressure: reproducibility and association with peripheral vascular disease. ( 24616810 )
2014
46
Clinical Trials in Peripheral Vascular Disease: Pipeline and Trial Designs: An Evaluation of the ClinicalTrials.gov Database. ( 25239436 )
2014
47
Association between frailty and subclinical peripheral vascular disease in a community-dwelling geriatric population: Taichung Community Health Study for Elders. ( 25164713 )
2014
48
Peripheral vascular disease is associated with increased pulse wave velocity and augmentation index: clinical implications. ( 25243631 )
2014
49
ICD-10 peripheral vascular disease. ( 24757907 )
2014
50
Association of interankle systolic blood pressure difference with peripheral vascular disease and left ventricular mass index. ( 23966444 )
2014

Variations for Peripheral Vascular Disease

Expression for Peripheral Vascular Disease

Search GEO for disease gene expression data for Peripheral Vascular Disease.

Pathways for Peripheral Vascular Disease

Pathways related to Peripheral Vascular Disease according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.51 ALB APOA1 APOB F2 F3 PLAT
2
Show member pathways
12.15 APOB F2 SELE SELP THBD
3
Show member pathways
12.09 ALB APOA1 APOB CRP F2 IL6
4
Show member pathways
12.07 F2 F3 PLAT SERPINC1 SERPINE1 THBD
5 12 PLAT SELE THBD VCAM1 VEGFA
6 11.94 ALB IL6 VCAM1 VEGFA
7 11.94 F2 F3 PLAT SERPINC1 SERPINE1 THBD
8 11.72 IL6 SERPINE1 VEGFA
9
Show member pathways
11.58 IL6 SELE VCAM1 VEGFA
10 11.5 F3 IL6 SELE SERPINE1 THBD VCAM1
11 11.45 APOB IL6 LPA PLAT SELP
12 11.42 IL6 SELE SELP VCAM1
13 11.34 ALB APOA1 F2
14 11.25 APOA1 IL6 SELE VCAM1
15 10.65 PLAT SERPINE1

GO Terms for Peripheral Vascular Disease

Cellular components related to Peripheral Vascular Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.88 APOA1 F3 PLAT THBD VCAM1 VEGFA
2 extracellular region GO:0005576 9.8 ACE ALB APOA1 APOB CRP F2
3 external side of plasma membrane GO:0009897 9.77 ACE F2 IL6 SELP VCAM1
4 blood microparticle GO:0072562 9.76 ALB APOA1 F2 SERPINC1
5 endoplasmic reticulum lumen GO:0005788 9.63 ALB APOA1 APOB F2 IL6 SERPINC1
6 platelet alpha granule lumen GO:0031093 9.62 ALB SERPINE1 VEGFA VWF
7 extracellular space GO:0005615 9.53 ACE ALB APOA1 APOB CRP F2
8 chylomicron GO:0042627 9.48 APOA1 APOB
9 intermediate-density lipoprotein particle GO:0034363 9.43 APOA1 APOB
10 extracellular exosome GO:0070062 10.03 ACE ALB APOA1 APOB CRP F2

Biological processes related to Peripheral Vascular Disease according to GeneCards Suite gene sharing:

(show all 30)
id Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.92 ALB APOA1 APOB IL6 SERPINC1
2 leukocyte migration GO:0050900 9.85 APOB F2 SELE SELP THBD
3 cellular protein metabolic process GO:0044267 9.8 ALB APOA1 APOB F2 IL6 SERPINC1
4 response to nutrient GO:0007584 9.79 APOA1 SERPINC1 VCAM1
5 response to wounding GO:0009611 9.79 F2 IL6 VWF
6 defense response to Gram-negative bacterium GO:0050829 9.73 IL6 SELP SERPINE1
7 response to lipopolysaccharide GO:0032496 9.73 APOB IL6 SELE SELP THBD VCAM1
8 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.71 SELE SELP VCAM1
9 lipoprotein metabolic process GO:0042157 9.71 ALB APOA1 APOB LPA
10 acute-phase response GO:0006953 9.69 CRP F2 IL6
11 leukocyte cell-cell adhesion GO:0007159 9.67 SELE SELP VCAM1
12 acute inflammatory response GO:0002526 9.65 IL6 VCAM1
13 fibrinolysis GO:0042730 9.65 F2 PLAT SERPINE1
14 positive regulation of blood coagulation GO:0030194 9.64 F2 SERPINE1
15 positive regulation of leukocyte migration GO:0002687 9.64 SELP VEGFA
16 low-density lipoprotein particle remodeling GO:0034374 9.63 APOB LPA
17 negative regulation of blood coagulation GO:0030195 9.63 SERPINE1 THBD
18 blood coagulation GO:0007596 9.63 F2 F3 PLAT SERPINC1 THBD VWF
19 positive regulation of positive chemotaxis GO:0050927 9.62 F3 VEGFA
20 lipoprotein biosynthetic process GO:0042158 9.61 APOA1 APOB
21 leukocyte tethering or rolling GO:0050901 9.61 SELE SELP VCAM1
22 neutrophil mediated immunity GO:0002446 9.6 ACE IL6
23 chylomicron assembly GO:0034378 9.59 APOA1 APOB
24 negative regulation of lipid storage GO:0010888 9.58 CRP IL6
25 chylomicron remodeling GO:0034371 9.58 APOA1 APOB
26 negative regulation of platelet activation GO:0010544 9.57 F2 THBD
27 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.55 ACE VEGFA
28 negative regulation of fibrinolysis GO:0051918 9.54 F2 SERPINE1 THBD
29 hemostasis GO:0007599 9.35 F2 F3 SERPINC1 THBD VWF
30 platelet degranulation GO:0002576 9.1 ALB APOA1 SELP SERPINE1 VEGFA VWF

Molecular functions related to Peripheral Vascular Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.73 F2 F3 LPA PLAT
2 phospholipid binding GO:0005543 9.58 APOA1 APOB F3
3 sialic acid binding GO:0033691 9.37 SELE SELP
4 glycoprotein binding GO:0001948 9.33 PLAT SELP VWF
5 oligosaccharide binding GO:0070492 9.32 SELE SELP
6 protease binding GO:0002020 9.26 F3 SERPINC1 SERPINE1 VWF
7 heparin binding GO:0008201 9.1 APOB F2 LPA SELP SERPINC1 VEGFA
8 protein binding GO:0005515 10.16 ALB APOA1 APOB CRP F2 F3

Sources for Peripheral Vascular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....